ArticleBMJ (Clinical research ed.)1999
Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure.
Article in BMJ (Clinical research ed.), 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Biochemical monitoring of patients treated with antihypertensive therapy for adverse drug reactions: a systematic review.Drug safety · 2011Pooled it
- Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963-2014).Population health metrics · 2017Article
- Article
- Adherence to renal function monitoring guidelines in patients starting antihypertensive therapy with diuretics and RAAS inhibitors: a retrospective cohort study.Drug safety · 2014Article
- Article
- Oversight: a retrospective study of biochemical monitoring in patients beginning antihypertensive drug treatment in primary care.British journal of clinical pharmacology · 2010Article
- Physicians make different decisions from nephrologists at serum creatinine 2.0 mg/dl.Clinical and experimental nephrology · 2009Article
- Management of acute renal failure in the elderly patient: a clinician's guide.Drugs & aging · 2008Review
- Late referral for assessment of renal failure.Journal of epidemiology and community health · 2005Article
- Diarrhoea, vomiting and ACE inhibitors:--an important cause of acute renal failure.Journal of human hypertension · 2003Article
- Use of calcium antagonists and worsening renal function in patients receiving angiotensin-converting-enzyme inhibitors.European journal of clinical pharmacology · 2003Article
- Effects of NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors.Drug safety · 2003Article
- Standardised monitoring of patients on long-term medication in primary care.The British journal of general practice : the journal of the Royal College of General Practitioners · 2002Article
- Audit of use of ACE inhibitors and monitoring in general practice. Guidelines on monitoring, on their own, are not sufficient.BMJ (Clinical research ed.) · 1999Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine the current pattern of use of angiotensin converting enzyme inhibitor and monitoring of renal function in general practice and to audit all admissions to a regional renal unit for uraemia related to use of these drugs.
designPostal questionnaire sent to 400 general practitioners; audit of clinical notes of all patients receiving these drugs in one large general practice; audit of all cases of uraemia (creatinine concentration >500 micromol/l) related to treatment presenting to hospital renal services over 12 months.
settingGeneral practices in the North Wales health authority and one in central Manchester. Regional renal unit in Salford.
main outcome measuresProportion of general practitioners who regularly monitored renal function before and after initiation of angiotensin converting enzyme inhibitors. Indications for treatment and details of monitoring of renal function in patients receiving these drugs. Incidence of related uraemia and evidence of comorbid disease, other aetiological factors, delayed detection, and patient outcome.
results277 (69%) general practitioners replied; 235 (85%) checked renal function before but only 93 (34%) after the start of treatment, and 42 (15%) never checked renal function. Angiotensin converting enzyme inhibitors were prescribed for 162 patients from a total of 3625 aged >35 years (mean age 66.4 (SD 15.9) years). Monitoring of renal function occurred before treatment in 55 (45%) and after start of treatment in 35 (29%) of the 122 patients treated in general practice. Angiotensin converting enzyme inhibitors could be causally implicated in 9 (7%) of 135 admissions for uraemia (mean age 74.2 (7. 2) v 62.1 (2.1) years; P<0.01). 3 patients had renovascular disease and 6 had congestive cardiac failure with another intercurrent illness. Renal function had not been checked in any patient after the start of treatment; mean duration of illness before admission was 10.5 (3.2) days. Mean length of hospital stay was 20.9 (10.4) days; there were 8 survivors.
conclusionCases of uraemia related to treatment with angiotensin converting enzyme inhibitors are still encountered and are often detected late because of lack of judicious monitoring of renal function in vulnerable, often elderly, patients, especially at times of intercurrent illness. Guidelines for appropriate monitoring of renal function may help to minimise the problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.